[{"id":"5f5a65f2-c9f4-4073-a80b-3cfdbd4c58d2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03382977","created_at":"2021-01-18T16:41:38.687Z","updated_at":"2024-07-02T16:35:14.613Z","phase":"Phase 1/2","brief_title":"Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects","source_id_and_acronym":"NCT03382977","lead_sponsor":"VBI Vaccines Inc.","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e lomustine • carmustine • VBI-1901"],"overall_status":"Recruiting","enrollment":" Enrollment 98","initiation":"Initiation: 12/06/2017","start_date":" 12/06/2017","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 08/01/2025","study_completion_date":" 08/01/2025","last_update_posted":"2024-03-15"}]